title: Inhibition of human group II phospholipase A2 by C-reactive protein in vitro.
abstract: Endotoxin or cytokine-induced expression of a secretory non-pancreatic phospholipase A2 (sPLA2) has been implicated in the pathogenesis of multisystem organ dysfunction or failure in patients with septic shock. Circulating sPLA2 levels increase as much as 1000-fold during the course of septic shock. However, the mode of regulation of the activity of this lipolytic enzyme is unknown, since circulating inhibitors have not been identified. We investigated the potential inhibitory activity of the acute phase reactant, C-reactive protein (CRP), a phospholipid-binding protein whose expression increases as much as 1000-fold during severe infections. Serum CRP and sPLA2 profiles were highly concordant in patients with septic shock. In studies in vitro, human CRP inhibited hydrolysis of PC-lyso-PC (2:1) multilamellar liposomes by human recombinant sPLA2 in a dose-dependent manner, with an apparent IC50 of 50 micrograms/ml CRP and maximal inhibition at 100 micrograms/ml. Inhibition of sPLA2 activity by CRP was substrate concentration-dependent, and increasing substrate concentrations reversed the inhibitory effect of CRP using the PC-lyso-PC system. Preincubation of CRP with phosphorylcholine led to a concentration-dependent loss of CRP-induced inhibition of substrate hydrolysis. These observations are consistent with a substrate-depletion model of inhibition of sPLA2 activity by CRP.
authors.affiliation: Wellesley Hospital Research Institute, University of Toronto, Ontario, Canada.
authors.forename: P
authors.initials: P
authors.lastname: Vadas
authors.forename: E
authors.initials: E
authors.lastname: Stefanski
authors.forename: B
authors.initials: B
authors.lastname: Grouix
authors.forename: B D
authors.initials: BD
authors.lastname: Schouten
authors.forename: W
authors.initials: W
authors.lastname: Pruzanski
mesh_terms: D002097:C-Reactive Protein / Q000378:metabolism / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D007700:Kinetics; D037102:Lectins / Q000494:pharmacology; D008081:Liposomes / Q000378:metabolism; D010713:Phosphatidylcholines / Q000378:metabolism; D010714:Phosphatidylethanolamines / Q000378:metabolism; D010741:Phospholipases A / Q000037:antagonists & inhibitors* / Q000097:blood; D054467:Phospholipases A2; D010767:Phosphorylcholine / Q000378:metabolism; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D012772:Shock, Septic / Q000097:blood / Q000201:enzymology*
chemical_list: D037102:Lectins; D008081:Liposomes; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D011994:Recombinant Proteins; C015323:limulin; D010767:Phosphorylcholine; D002097:C-Reactive Protein; D010741:Phospholipases A; D054467:Phospholipases A2; D002118:Calcium